ArticleBMC pulmonary medicine2026
Assessment of the modified glasgow prognostic scale and inflammatory parameters as a new prognostic indicator in pulmonary thromboembolism patients.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
INTRODUCTION AND
objectiveAcute Pulmonary Embolism (PE) is a common and life-threatening condition, necessitating early prognostic evaluation. While various prognostic scoring systems exist, most lack parameters reflecting the inflammatory aspect of PE. This study aimed to assess the prognostic significance of inflammatory markers, particularly the modified Glasgow Prognostic Scale (mGPS), and their relationship with established prognostic tools like the Pulmonary Embolism Severity Index (PESI). MATERIALS AND
methodsWe retrospectively analyzed 436 patients diagnosed with acute PE and hospitalized in the Department of Chest Diseases at Dicle University Medical Faculty between January 2020 and January 2024. Patients with incomplete records were excluded, leaving 334 for final analysis. mGPS scores were calculated and categorized as 0, 1, or 2. We examined associations between mGPS scores, PESI, 30-day and 90-day mortality, and other inflammatory parameters.
resultsThe mean age of the cohort was 61.52 ± 17.12 years. Patients with an mGPS score of 2 had significantly higher PESI scores (p < 0.001) and increased 30-day and 90-day mortality rates (p < 0.001). A strong, positive correlation was observed between mGPS and PESI (r = 0.536, p < 0.001). ROC analysis identified albumin (AUC: 0.878) and oxygen saturation (AUC: 0.854) as the best-performing predictors for PESI classification. A predictive model combining mGPS, oxygen saturation, and systolic blood pressure outperformed sPESI in mortality prediction (AUC: 0.748, cut-off: 2.5).
conclusionThe mGPS score is a significant prognostic marker for 30- and 90-day mortality in PE patients and outperforms sPESI in predicting PESI scores. Our simplified model incorporating mGPS, oxygen saturation, and systolic blood pressure provides a practical and effective alternative to existing tools for prognostic evaluation in acute PE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.